RxDoctor Payments Data

Michael Ciccone, MD

Urology · Belleville, NJNPI 1649294034

Payments from drug & device makers

$11,407in general payments, 2019–2025

Across 97 payments — averaging $117.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$8K
  • Bayer$1K
  • Astellas Pharma US Inc$451
  • Procept Biorobotics Corporation$269
  • Boston Scientific$184
  • Axonics, Inc.$146
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$1,12232%
  • Food & beverage$2,17063%
  • Education$1655%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,407 in reported general payments places this provider in the 80th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$344,462
Medicare patients
568
Services billed
6,606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron242$141,960
GemtesaVibegron99$59,000
Dutasteride144$6,020
Solifenacin Succinate138$5,878
Tamsulosin Hcl460$5,232
Testosterone15$4,976
Tolterodine Tartrate ErTolterodine Tartrate75$3,907
Trospium Chloride ErTrospium Chloride15$3,522
Alfuzosin Hcl ErAlfuzosin Hcl123$1,767
Estradiol22$1,282
Silodosin26$1,163
Oxybutynin Chloride ErOxybutynin Chloride41$1,034
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip48$995
Cephalexin152$551
Finasteride37$542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$451$141,960242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 401 urology providers in New Jersey.

Other urology in Belleville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →